Latest from Winship

Bassel El-Rayes, MD, chief clinical research scientist, Winship Cancer Institute of Emory University, discusses methods of locoregional therapy in metastatic colorectal cancer.
A broader set of clinical trial eligibility criteria proposed by the American Society of Clinical Oncology and Friends of Cancer Research would nearly double the number of patients with advanced non-small cell lung cancer available for enrollment.
Bassel El-Rayes, MD, chief clinical research scientist, Winship Cancer Institute of Emory University, discusses considerations for locoregional therapy versus resection in patients with colorectal cancer.
Bassel El-Rayes, MD, further discusses the role of locoregional approaches in borderline and unresectable patients with metastatic colorectal cancer.
Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the impact of osimertinib (Tagrisso) in both clinical trial and real-world settings.
Suresh S. Ramalingam, MD, describes findings with osimertinib, and discusses the emerging body of data exploring primary and acquired resistance mechanisms to the third-generation agent.
Sagar Lonial, MD, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses encouraging data with emerging agents in myeloma.
Sagar Lonial, MD, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the treatment of patients with late relapse myeloma.
Publication Bottom Border
Border Publication
x